Knockdown of hypoxia-inducible factor-1α in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate

被引:70
作者
Li, J
Shi, MX
Cao, Y
Yuan, WS
Pang, TX
Li, BZ
Sun, Z
Chen, L
Zhao, RCH [1 ]
机构
[1] Chinese Acad Med Sci, Inst Basic Med Sci, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci, Sch Basic Med, Ctr Excellence Tissue Engn, Beijing, Peoples R China
[3] Peking Union Med Coll, Beijing, Peoples R China
[4] Peking Union Med Coll, Tianjin, Peoples R China
[5] Chinese Acad Sci, State Key Lab Expt Hematol, Inst Hematol & Blood Transfus Hosp, Tianjin, Peoples R China
关键词
HIF-1; alpha; RNA interference; MCF-7; glycolysis; angiogenesis; tumor growth; methotrexate; xenograft;
D O I
10.1016/j.bbrc.2006.02.094
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The hypoxia-inducible factor (HIF) 1 alpha a is a key regulator of the cellular response to oxygen deprivation. Specific disruption of the HIF-1 pathway is important for exploring its role in tumor biology and developing more efficient weapons to treat cancer. In this study, we stably transfected human breast tumor MCF-7 cells with short hairpin RNA expression vectors targeting HIF-1 alpha. After knockdown of HIF-1 alpha, hypoxia-induced expression of its target genes such as vascular endothelial growth factor, Glut-1, phosphoglycerate kinase, and P-glycoprotein were markedly attenuated. Moreover, HIF-alpha knockdown was found to suppress the shift from S-phase to G(1) induced by hypoxia and increase drug sensitivity to methotrexate. The growth rates of HIF1 alpha-knockdown tumors were drastically retarded in both Subcutaneous and orthotopic xenograft models, which were accompanied by decreased angiogenesis and reduced expression of glucose transporter in tissue sections. These data demonstrate that HIF-1 alpha knockdown reduces tumorigenicity of MCF-7 cells and Suggest a promising combination of both anti-HIF-1 strategy and traditional chemotherapy to improve cancer treatment. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1341 / 1351
页数:11
相关论文
共 35 条
[1]   Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts [J].
Bhujwalla, ZM ;
Artemov, D ;
Natarajan, K ;
Ackerstaff, E ;
Solaiyappan, M .
NEOPLASIA, 2001, 3 (02) :143-153
[2]   The hypoxic response of tumors is dependent on their microenvironment [J].
Blouw, B ;
Song, HQ ;
Tihan, T ;
Bosze, J ;
Ferrara, N ;
Gerber, HP ;
Johnson, RS ;
Bergers, G .
CANCER CELL, 2003, 4 (02) :133-146
[3]   Levels of hypoxia-inducible factor-1α during breast carcinogenesis [J].
Bos, R ;
Zhong, H ;
Hanrahan, CF ;
Mommers, ECM ;
Semenza, GL ;
Pinedo, HM ;
Abeloff, MD ;
Simons, JW ;
van Diest, PJ ;
van der Wall, E .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04) :309-314
[4]   Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo [J].
Cao, Y ;
Sun, Z ;
Liao, LM ;
Meng, Y ;
Han, Q ;
Zhao, RCH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 332 (02) :370-379
[5]   Role of HIF-1α or in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis [J].
Carmeliet, P ;
Dor, Y ;
Herbert, JM ;
Fukumura, D ;
Brusselmans, K ;
Dewerchin, M ;
Neeman, M ;
Bono, F ;
Abramovitch, R ;
Maxwell, P ;
Koch, CJ ;
Ratcliffe, P ;
Moons, L ;
Jain, RK ;
Collen, D ;
Keshet, E .
NATURE, 1998, 394 (6692) :485-490
[6]   Dominant-negative hypoxia-inducible factor-1α reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism [J].
Chen, J ;
Zhao, SJ ;
Nakada, K ;
Kuge, Y ;
Tamaki, N ;
Okada, F ;
Wang, JX ;
Shindo, M ;
Higashino, F ;
Takeda, K ;
Asaka, M ;
Katoh, H ;
Sugiyama, T ;
Hosokawa, M ;
Kobayashi, M .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (04) :1283-1291
[7]   Positron emission tomography scanning: Current and future applications [J].
Czernin, J ;
Phelps, ME .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :89-112
[8]   Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer:: Retrospective study in a series of 745 patients [J].
Dales, JP ;
Garcia, S ;
Meunier-Carpentier, S ;
Andrac-Meyer, L ;
Haddad, O ;
Lavaut, MN ;
Allasia, C ;
Bonnier, P ;
Charpin, C .
INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (05) :734-739
[9]  
Eschmann SM, 2005, J NUCL MED, V46, P253
[10]  
Feldser D, 1999, CANCER RES, V59, P3915